drugset
drugset / Trial / NCT05030506

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

NCT05030506 ↗

Phase 1 Active not recruiting 45 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy of belzutifan as monotherapy followed by belzutifan+lenvatinib combination therapy, as well as belzutifan combined with lenvatinib and pembrolizumab in China participants with advanced renal cell carcinoma.

Timeline

Start
2021-10-13
Primary completion
2027-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Belzutifan Small molecule 120 mg Oral
Subject Lenvatinib Small molecule 20 mg Oral
Subject Pembrolizumab Monoclonal antibody 400 mg Intravenous

Indications

renal cell carcinoma